Home›Trial›NCT06333704
NCT06333704RECRUITING

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.

Study Summary

The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety related information in South-Korean population.

Conditions
SARS-CoV-2
Interventions / Drugs
SPIKEVAX BivalentSPIKEVAX X
View on ClinicalTrials.gov ↗
Sponsor
MRNA
Moderna Inc
mRNA Therapeutics
C64/100
Study Details
Enrollment4206 participants
Primary Completion—
Lead SponsorModernaTX, Inc.
Data Retrieved2026-04-11 02:55:38.209185+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 4,206 participants
Sponsor Catalyst Profile

Moderna Inc (MRNA) is the sponsoring company for this trial. BiotechSign currently grades this company C (64/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

MRNA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.